NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer

The following documents are made available to the consultees and commentators:

1. **Response to consultee, commentator and public comments on the second and third Appraisal Consultation Documents (ACD)**

2. **Consultee and commentator comments on the third Appraisal Consultation Document** from:
   - Lilly UK (3 documents)
     - Revised estimate of the number of patients eligible to receive pemetrexed
     - Updated revised final estimate of the number of patients eligible to receive pemetrexed
   - Royal College of Physicians

   A no 'comments' response was received from the Royal College of Nursing and the Department of Health.

Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted.